Nattokinase: An oral antithrombotic agent for the prevention of cardiovascular disease

Another nattokinase review, this one notable for pairing the antithrombotic case with the science of making the enzyme at scale.

On mechanism, the authors describe nattokinase dissolving clots through more than one route — directly breaking down fibrin and degrading PAI-1 (a brake on the body’s own clot-clearing system) — with oral bioavailability and a reassuring safety record across animal and human studies. The distinctive angle is production: recombinant “plant molecular farming” methods that could make the enzyme cheaply at scale.

The practical takeaway is the same measured one that runs through the credible nattokinase literature: a plausible natural antithrombotic, but one that needs rigorous clinical trials before it can be recommended over established anticoagulants. The status-quo friction is a low-cost, unpatentable agent against a patented-drug market.

We rate the evidence moderate: a broad, 80-reference, NIH-funded review spanning mechanism through manufacturing, but narrative and from authors involved in production research. Its clinical significance is moderate — real interest in an accessible antithrombotic, gated by the absence of large head-to-head trials. Read it alongside the rigorous meta-analysis (Li et al., 2023) for the difference between mechanistic promise and proven effect.